Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis
Received 22 August 2018
Accepted for publication 7 November 2018
Published 27 February 2019 Volume 2019:11 Pages 1907—1920
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Justinn Cochran
Peer reviewer comments 3
Editor who approved publication: Dr Rituraj Purohit
Xu-ping Gao,1,* Yan-hua Liu,2,* Ze-ying Liu,1 Li-jun Wang,3 Chun-xia Jing,1 Sui Zhu,4 Fang-fang Zeng1
1Department of Epidemiology, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China; 2Department of Nutrition, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China; 3Department of Nutrition, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China; 4Department of Medical Statistics, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China
*These authors contributed equally to this work
Introduction: In this meta-analysis, we analyzed retrospective cohort studies that assessed the prognostic potential of the pretreatment lymphocyte-to-monocyte ratio (LMR) among patients with ovarian cancer (OC).
Materials and methods: We comprehensively searched electronic databases, including PubMed and Embase, from inception through October 2018. A random-effects model was used to calculate pooled HRs and their 95% CIs for overall survival (OS) and progression-free survival (PFS). The low LMR group was treated as the reference group.
Results: Twelve studies, including 3,346 OC cases at baseline, were included. Overall, our results indicated that LMR was positively associated with both OS (HR: 1.85, 95% CI: 1.50–2.28, P<0.001; I2=76.5%) and PFS (HR: 1.70, 95% CI: 1.49–1.94, P<0.001; I2=24.4%) among OC patients. Stratified analyses indicated that, for OS, the LMR’s protective effect was more evident in studies conducted among younger patients (<55 years) than in those conducted among older patients (≥55 years; P for interaction =0.017), which was confirmed by meta-regression
Conclusion: This study suggested that a higher pretreatment LMR level was associated with a favorable prognosis among OC patients. Future large-scale prospective clinical trials are needed to confirm the prognostic value of LMR among OC patients.
Keywords: ovarian cancer, lymphocyte-to-monocyte ratio, prognosis, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]